Therapeutics

Bispecific Antibody That Binds To Both Immune & Cancer Cells

Receptor

Antibody

Conjugated

Engager

Receptor Antibody Conjugated Engager (RACE) is an advanced immunotherapy that combines a switchable clinical antibody (Fab) with strong tumor antigen affinity. As a customizable platform, it targets multiple cancer types, heralding a new era in tailored cancer treatments.

How It Works

RACE Mode of Action

Bispecific Antibody Targeting 4-1BB

RACE employs 4-1BB ligands to direct T and NK cells to tumors, creating an immunological synapse and activating T cells via 4-1BB receptor hyper-clustering. RACE's dual binding and ability to induce immune cell-tumor conjugation enhances its therapeutic impact.

RACE Natural Ligand Structure

Empowering Natural Ligands

The Receptor Antibody Conjugated Engager (RACE) harnesses natural ligands to ensure a stronger affinity with EGFR receptors, vital for more effective T cell clustering. These natural interactions propel RACE to the forefront, evidenced by a fivefold increase in T cell activation and a fourfold surge in cytokine release, outperforming competitor therapies and marking a leap in the effectiveness of cancer immunotherapy.